SG11201810359PA - (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders - Google Patents

(2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders

Info

Publication number
SG11201810359PA
SG11201810359PA SG11201810359PA SG11201810359PA SG11201810359PA SG 11201810359P A SG11201810359P A SG 11201810359PA SG 11201810359P A SG11201810359P A SG 11201810359PA SG 11201810359P A SG11201810359P A SG 11201810359PA SG 11201810359P A SG11201810359P A SG 11201810359PA
Authority
SG
Singapore
Prior art keywords
international
week
compound
pct
oxadiazol
Prior art date
Application number
SG11201810359PA
Other languages
English (en)
Inventor
Remy Luthringer
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of SG11201810359PA publication Critical patent/SG11201810359PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
SG11201810359PA 2016-05-25 2017-05-23 (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders SG11201810359PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341517P 2016-05-25 2016-05-25
US201662373720P 2016-08-11 2016-08-11
PCT/US2017/034036 WO2017205399A1 (en) 2016-05-25 2017-05-23 (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders

Publications (1)

Publication Number Publication Date
SG11201810359PA true SG11201810359PA (en) 2018-12-28

Family

ID=59034882

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201810359PA SG11201810359PA (en) 2016-05-25 2017-05-23 (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders
SG10202011471XA SG10202011471XA (en) 2016-05-25 2017-05-23 (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202011471XA SG10202011471XA (en) 2016-05-25 2017-05-23 (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders

Country Status (10)

Country Link
US (2) US20190183874A1 (zh)
EP (1) EP3463357B1 (zh)
JP (2) JP2019516758A (zh)
KR (2) KR20190013847A (zh)
CN (2) CN114848641A (zh)
ES (1) ES2964790T3 (zh)
PH (1) PH12018502446A1 (zh)
SG (2) SG11201810359PA (zh)
TW (2) TW202243675A (zh)
WO (1) WO2017205399A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7439096B2 (ja) * 2018-09-04 2024-02-27 田辺三菱製薬株式会社 疼痛を処置するためにフェノキシプロピルアミン化合物を使用する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100799134B1 (ko) * 1999-05-24 2008-01-29 미츠비시 웰파마 가부시키가이샤 페녹시프로필아민 화합물
SA08280759B1 (ar) * 2007-01-10 2011-05-04 سولفاي فارماسوتيكالز بي . في مركبات من عوامل مضادة لشبيه القنب – cb1 ومكونات هيكلية من مثبطات إعادة إمتصاص السيروتونين بأندلابين أو فلوكسامين
AU2014209200B2 (en) * 2013-01-24 2018-11-01 Minerva Neurosciences, Inc. Use of phenoxypropylamine compounds to treat depression

Also Published As

Publication number Publication date
SG10202011471XA (en) 2021-01-28
CN114848641A (zh) 2022-08-05
TW202243675A (zh) 2022-11-16
ES2964790T3 (es) 2024-04-09
EP3463357B1 (en) 2023-09-20
KR20190013847A (ko) 2019-02-11
PH12018502446A1 (en) 2019-09-09
CN109640990A (zh) 2019-04-16
JP7309824B2 (ja) 2023-07-18
JP2022031814A (ja) 2022-02-22
US20230248714A1 (en) 2023-08-10
TW201808285A (zh) 2018-03-16
EP3463357A1 (en) 2019-04-10
US20190183874A1 (en) 2019-06-20
WO2017205399A1 (en) 2017-11-30
KR20230116950A (ko) 2023-08-04
JP2019516758A (ja) 2019-06-20

Similar Documents

Publication Publication Date Title
SG11201900135YA (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201808990QA (en) Compositions for topical application of compounds
SG11201809714TA (en) Piperidines as menin inhibitors
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201407200TA (en) Liquid formulation
SG11201909376TA (en) Crystalline forms of a jak inhibitor compound
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201811686UA (en) 18f-labeled triazole containing psma inhibitors
SG11201808686VA (en) Synthesis of indazoles
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201907774VA (en) Sulfoximine glycosidase inhibitors
SG11201901850XA (en) Dopamine-b-hydroxylase inhibitors
SG11201809162XA (en) 6-aminopyridin-3-yl thiazoles as modulators of ror?t
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201803816RA (en) Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease
SG11201900214UA (en) Iso-citrate dehydrogenase (idh) inhibitor
SG11201407303SA (en) Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders